Genetic risk prediction: Individualized variability in susceptibility to toxicants

Annual Review of Pharmacology and Toxicology

Volumn 53, Issue , 2013, Pages 355-375

  Nebert, Daniel W ^a,b   Zhang, Ge ^a   Vesell, Elliot S ^c  

^a Division of Human Genetics   (United States)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

environmental genetics; epigenetics; genetic risk prediction; genome wide association studies; Mendelian trait; multifactorial trait; toxicogenetics; toxicogenomics

Indexed keywords

ANILINE; ARSENIC; CYTOCHROME P450 1A2; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; XENOBIOTIC AGENT;

ENVIRONMENTAL DISEASE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HEMOLYTIC ANEMIA; HERITABILITY; HUMAN; HUMAN GENOME PROJECT; MULTIFACTORIAL INHERITANCE; PHENOTYPE; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STATISTICAL ANALYSIS; TOXICOGENETICS;

ANIMALS; ENVIRONMENT; GENETIC PREDISPOSITION TO DISEASE; HAZARDOUS SUBSTANCES; HUMANS; RISK ASSESSMENT; TOXICOGENETICS; XENOBIOTICS;

EID: 84872241143     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-011112-140241     Document Type: Review

References (75)

1. Nebert DW, Dalton TP. 2006. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat. Rev. Cancer 6:947-60
2. Nebert DW, Zhang G, Vesell ES. 2008. From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab. Rev. 40:187-224
3. Nebert DW. 1989. The Ah locus: genetic differences in toxicity, cancer, mutation and birth defects. Crit. Rev. Toxicol. 20:153-74
4. Poland AP, Glover E, Robinson JR, Nebert DW. 1974. Genetic expression of aryl hydrocarbon hydroxylase activity. Induction of monooxygenase activities and cytochrome P1-450 formation by 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin in mice genetically "nonresponsive" to other polycyclic aromatic hydrocarbons. J. Biol. Chem. 249:5599-606
5. Poland A, Palen D, Glover E. 1994. Analysis of the four alleles of the murine aryl hydrocarbon receptor. Mol. Pharmacol. 46:915-21
6. Price-Evans DA, Manley KA, McKusick VA. 1960. Genetic control of isoniazid metabolism in man. Br. Med. J. 2:485-91
7. McDonagh EM, Thorn CF, Bautista JM, Youngster I, Altman RB, KleinTE. 2012. PharmGKB summary: very important pharmacogene information for G6PD. Pharmacogenet. Genomics 22:219-28
8. Nebert DW, Jorge-Nebert LF. 2007. Pharmacogenetics and pharmacogenomics. In Emery & Rimoin's Principles and Practice of Medical Genetics, ed. DL Rimoin, JM Connor, RE Pyeritz, BR Korf, pp. 456-98. London: Churchill Livingstone
9. Lewalter J, Korallus U. 1985. Blood protein conjugates and acetylation of aromatic amines. New findings on biological monitoring. Int. Arch. Occup. Environ. Health 56:179-96
10. Weis BK, Balshaw D, Barr JR, Brown D, Ellisman M, et al. 2005. Personalized exposure assessment: promising approaches for human environmental health research. Environ. Health Perspect. 113:840-48
11. Kerns RT, Bushel PR. 2012. The impact of classification of interest on predictive toxicogenomics. Front. Genet. 3:1-5
12. Birney E, Stamatoyannopoulos JA, Dutta A, Guigo R, Gingeras TR, et al. 2007. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447:799-816
13. Lettice LA, Heaney SJ, Purdie LA, Li L, de Beer P, et al. 2003. A long-range Shh enhancer regulates expression in the developing limb and fin and is associated with preaxial polydactyly. Hum. Mol. Genet. 12:1725-35
14. Rosenberg NA, Huang L, JewettEM, Szpiech ZA, Jankovic I, Boehnke M. 2010. Genome-wide association studies in diverse populations. Nat. Rev. Genet. 11:356-66
15. McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, et al. 2008. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat. Rev. Genet. 9:356-69
16. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, et al. 2009. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc. Natl. Acad. Sci. USA 106:9362-67
17. Lander ES. 2011. Initial impact of the sequencing of the human genome. Nature 470:187-97
18. Goldstein DB. 2011. The importance of synthetic associations will only be resolved empirically. PLoS Biol. 9:e1001008
19. Manolio TA. 2010. Genome-wide association studies and assessment of the risk of disease. N. Engl. J. Med. 363:166-76
20. Wray NR, Purcell SM, Visscher PM. 2011. Synthetic associations created by rare variants do not explain most GWAS results. PLoS Biol. 9:e1000579
21. Anderson CA, Soranzo N, Zeggini E, Barrett JC. 2011. Synthetic associations are unlikely to account for many common disease genome-wide association signals. PLoS Biol. 9:e1000580
22. Feigl B, Morris CP. 2011. The challenge of predicting macular degeneration. Curr. Med. Res. Opin. 27:1745-48
23. Naser SA, Arce M, Khaja A, Fernandez M, Naser N, et al. 2012. Role of ATG16L, NOD2 and IL23R in Crohn's disease pathogenesis. World J. Gastroenterol. 18:412-24
24. Anzai N, Jutabha P, Amonpatumrat-Takahashi S, Sakurai H. 2012. Recent advances in renal urate transport: characterization of candidate transporters indicated by genome-wide association studies. Clin. Exp. Nephrol. 16:89-95
25. Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, et al. 2011. Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology 53:336-45
26. Feng Q, Wilke RA, Baye TM. 2012. Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions. Pharmacogenomics 13:579-94
27. Zhang Q, Lin CY, Dong Q, Wang J, Wang W. 2011. Relationship between HLA-DRB1 polymorphism and susceptibility or resistance to multiple sclerosis in Caucasians: a meta-analysis of non-family-based studies. Autoimmun. Rev. 10:474-81
28. Jakobsdottir J, Gorin MB, Conley YP, Ferrell RE, Weeks DE. 2009. Interpretation of genetic association studies: markers with replicated highly significant odds ratios may be poor classifiers. PLoS Genet. 5:e1000337
29. Need AC, GeD, Weale ME, Maia J, Feng S, et al. 2009. A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS Genet. 5:e1000373
30. Gibson G. 2009. Decanalization and the origin of complex disease. Nat. Rev. Genet. 10:134-40
31. Gibson G. 2010. Hints of hidden heritability in GWAS. Nat. Genet. 42:558-60
32. Yang J, Ferreira T, Morris AP, Medland SE, Madden PA, et al. 2012. Conditional and jointmultiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. Nat. Genet. 44:369-75
33. Weedon MN, Lango H, Lindgren CM, Wallace C, Evans DM, et al. 2008. Genome-wide association analysis identifies 20 loci that influence adult height. Nat. Genet. 40:575-83
34. Lettre G, Jackson AU, Gieger C, Schumacher FR, Berndt SI, et al. 2008. Identification of ten loci associated with height highlights new biological pathways in human growth. Nat. Genet. 40:584-91
35. Gudbjartsson DF, Walters GB, Thorleifsson G, StefanssonH, Halldorsson BV, et al. 2008.Manysequence variants affecting diversity of adult human height. Nat. Genet. 40:609-15
36. Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN, et al. 2010. Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature 467:832-38
37. Park JH, Wacholder S, Gail MH, Peters U, Jacobs KB, et al. 2010. Estimation of effect-size distribution from genome-wide association studies and implications for future discoveries. Nat. Genet. 42:570-75
38. Yang J, Benyamin B, McEvoy BP, Gordon S, Henders AK, et al. 2010. Common SNPs explain a large proportion of the heritability for human height. Nat. Genet. 42:565-69
39. Yang J, Manolio TA, Pasquale LR, Boerwinkle E, Caporaso N, et al. 2011. Genome partitioning of genetic variation for complex traits using common SNPs. Nat. Genet. 43:519-25
40. Dubois L, Ohm KK, Girard M, Tatone-Tokuda F, Perusse D, et al. 2012. Genetic and environmental contributions to weight, height, and BMI from birth to 19 years of age: an international study of over 12, 000 twin pairs. PLoS ONE 7:e30153
41. Chan Y, Holmen OL, Dauber A, Vatten L, Havulinna AS, et al. 2011. Common variants show predicted polygenic effects on height in the tails of the distribution, except in extremely short individuals. PLoS Genet. 7:e1002439
42. Dermitzakis ET, Clark AG. 2009. Genetics: life after GWA studies. Science 326:239-40
43. Gibson G. 2012. Rare and common variants: twenty arguments. Nat. Rev. Genet. 13:135-45
44. Bamshad MJ, Ng SB, Bigham AW, Tabor HK, Emond MJ, et al. 2011. Exome sequencing as a tool for Mendelian disease gene discovery. Nat. Rev. Genet. 12:745-55
45. Ashley EA, Butte AJ, Wheeler MT, Chen R, Klein TE, et al. 2010. Clinical assessment incorporating a personal genome. Lancet 375:1525-35
46. Cirulli ET, Goldstein DB. 2010. Uncovering the roles of rare variants in common disease through wholegenome sequencing. Nat. Rev. Genet. 11:415-25
47. Sulem P, Gudbjartsson DF, Walters GB, Helgadottir HT, Helgason A, et al. 2011. Identification of low-frequency variants associated with gout and serum uric acid levels. Nat. Genet. 43:1127-30
48. Zeggini E. 2011. Next-generation association studies for complex traits. Nat. Genet. 43:287-88
49. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, et al. 2009. Finding the missing heritability of complex diseases. Nature 461:747-53
50. Martens JH, Stunnenberg HG, Logie C. 2011. The decade of the epigenomes? Genes Cancer 2:680-87
51. Cedar H, Bergman Y. 2012. Programming of DNA methylation patterns. Annu. Rev. Biochem. 81:97-117
52. Abdellatif M. 2012. Differential expression of microRNAs in different disease states. Circ. Res. 110:638-50
53. Ammerpoht O, Siebert R. 2011. How to analyse epigenetic marks? Pediatr. Endocrinol. Rev. 9(Suppl. 1):511-14
54. Alabert C, Groth A. 2012. Chromatin replication and epigenome maintenance. Nat. Rev. Mol. Cell Biol. 13:153-67
55. Petronis A. 2010. Epigenetics as a unifying principle in the aetiology of complex traits and diseases. Nature 465:721-27
56. Skinner MK. 2011. Environmental epigenomics and disease susceptibility. EMBO Rep. 12:620-22
57. Rakyan VK, Down TA, Balding DJ, Beck S. 2011. Epigenome-wide association studies for common human diseases. Nat. Rev. Genet. 12:529-41
58. Bell JT, Pai AA, Pickrell JK, Gaffney DJ, Pique-Regi R, et al. 2011. DNA methylation patterns associate with genetic and gene expression variation in HapMap cell lines. Genome Biol. 12:R10
59. Kaminsky ZA, TangT, Wang SC, Ptak C, Oh GH, et al. 2009.DNAmethylation profiles in monozygotic and dizygotic twins. Nat. Genet. 41:240-45
60. Nebert DW, Dalton TP, Okey AB, Gonzalez FJ. 2004. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J. Biol. Chem. 279:23847-50
61. Nakajima M, YokoiT, Mizutani M, Kinoshita M, FunayamaM, Kamataki T. 1999. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J. Biochem. 125:803-8
62. Chen X, Wang L, Zhi L, Zhou G, Wang H, et al. 2005. The-113G A polymorphism in CYP1A2 affects the caffeine metabolic ratio in a Chinese population. Clin. Pharmacol. Ther. 78:249-59
63. Cornelis MC, El-Sohemy A, Kabagambe EK, Campos H. 2006. Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA 295:1135-41
64. Jiang Z, Dragin N, Jorge-Nebert LF, Martin MV, Guengerich FP, et al. 2006. Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype. Pharmacogenet. Genomics 16:359-67
65. Wilson Sayres MA, Brookes AJ, Chanock SJ, Cheung VG, Goldstein DB, et al. 2012. HGV2011: Personalized genomic medicine meets the incidentalome. Hum. Mutat. 33:582-85
66. Cornelis MC, Monda KL, Yu K, Paynter N, Azzato EM, et al. 2011. Genome-wide meta-analysis identifies regions on 7p21 (AHR) and 15q24 (CYP1A2) as determinants of habitual caffeine consumption. PLoSGenet. 7:e1002033
67. Fisher R. 1918. The correlation between relatives on the supposition ofMendelian inheritance. Trans. R. Soc. Edinb. 52:399-433
68. Wang X, Elston RC, Zhu X. 2011. Statistical interaction in human genetics: How should we model it if we are looking for biological interaction? Nat. Rev. Genet. 12:74
69. Pierce BL, Kibriya MG, Tong L, Jasmine F, Argos M, et al. 2012. Genome-wide association study identifies chromosome 10q24.32 variants associated with arsenic metabolism and toxicity phenotypes in Bangladesh. PLoS Genet. 8:e1002522
70. Hill WG, Goddard ME, Visscher PM. 2008. Data and theory point to mainly additive genetic variance for complex traits. PLoS Genet. 4:e1000008
71. Zuk O, Hechter E, Sunyaev SR, LanderES. 2012. Themystery of missing heritability: Genetic interactions create phantom heritability. Proc. Natl. Acad. Sci. USA 109:1193-98
72. Ehrenreich IM, Bloom J, Torabi N, Wang X, Jia Y, Kruglyak L. 2012. Genetic architecture of highly complex chemical resistance traits across four yeast strains. PLoS Genet. 8:e1002570
73. Hebebrand J, Volckmar AL, Knoll N, Hinney A. 2010. Chipping away the 'missing heritability': GIANT steps forward in the molecular elucidation of obesity-but still lots to go. Obes. Facts 3:294-303
74. Zhao J, Bradfield JP, Zhang H, Annaiah K, Wang K, et al. 2010. Examination of all type-2 diabetesGWAS loci reveals HHEX-IDE as a locus influencing pediatric BMI. Diabetes 59:751-55
75. Peterson RE, Maes HH, Holmans P, Sanders AR, Levinson DF, et al. 2011. Genetic risk sum score comprised of common polygenic variation is associated with body mass index. Hum. Genet. 129:221-30